Rhône-Poulenc to focus biotech work on gene therap...[Nature. 1994] - PubMed Result

SearchDatabase nameforSearch term

Advanced Search

Your browser version may not work well with NCBI's Web applications. More information here...

Display Show

All: 1

Review: 0

Click to change filter selection through MyNCBI.

1: Nature. 1994 May 12;369(6476):92. Links

Rhône-Poulenc to focus biotech work on gene therapy.

PMID: 8177328 [PubMed - indexed for MEDLINE]

Related articles

[Initiative of the drug industry]
Bull Cancer. 1995 Mar; 82(3):221-2.

[Bull Cancer. 1995]
Rhône-Poulenc lifts Institut Mérieux stake.
Nature. 1993 Oct 7; 365(6446):478.

[Nature. 1993]
Rhône-Poulenc: from bioscience to markets. The how, why, and when of the world's seventh-largest chemicals company.
Biotechnology (N Y). 1993 Jul; 11(7):798-801.

[Biotechnology (N Y). 1993]
ReviewBiotech pharmaceuticals and biotherapy: an overview.
J Pharm Pharm Sci. 1998 May-Aug; 1(2):48-59.

[J Pharm Pharm Sci. 1998]
ReviewINGN 201: Ad-p53, Ad5CMV-p53, Adenoviral p53, INGN 101, p53 gene therapy--Introgen, RPR/INGN 201.
BioDrugs. 2003; 17(3):216-22.

[BioDrugs. 2003]
» See reviews... | » See all...

Recent Activity

Clear Turn Off Turn On

Rhône-Poulenc to focus biotech work on gene therapy.Rhône-Poulenc to focus biotech work on gene therapy.

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Display Show